AVENUE THERAPEUTICS, INC.

Insiders Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-20 EDT			5-day change	1st Jan Change
3.81 ^USD	+2.14%		-3.54%	-68.45%

05-16	Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	CI
05-15	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Insider Buy: Avenue Therapeutics	23-09-12	MT
Avenue Therapeutics, Inc. Announces Board Changes	23-03-08	CI
Avenue Therapeutics, Inc. Announces Board Resignations	22-11-04	CI
Avenue Therapeutics, Inc. Appoints Alexandra Maclean as Chief Executive Officer	22-08-03	CI
Avenue Therapeutics, Inc. Announces Management Changes	22-05-16	CI
Avenue Therapeutics, Inc. Announces CEO Changes	22-03-30	CI
Avenue Therapeutics, Inc. Announces Executive Changes	22-03-30	CI
Avenue Therapeutics, Inc. Appoints Curtis Oltmans as A New Member of the Board	21-04-05	CI
Avenue Therapeutics, Inc. Announces Thomas G. Moore to Resign from the Board of Directors of the Company, Effective December 31, 2020	20-12-04	CI
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors	19-08-01	CI
Avenue Therapeutics, Inc. Announces Appointment of Thomas G. Moore to Board of Directors	19-04-30	CI
Avenue Therapeutics, Inc. Announces Board Resignations	19-04-11	CI
Avenue Therapeutics, Inc. Announces Management Changes	19-02-11	CI
Avenue Therapeutics, Inc. Announces Executive Changes	17-08-15	CI
Avenue Therapeutics, Inc. Appoints Lucy Lu as Chief Executive Officer and President	17-06-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW